Formulary
Moxonidine: Indications, Dosing, Side Effects and Interactions
Moxonidine clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Moxonidine: Indications, Dosing, Side Effects and Interactions
Moxonidine clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Mild to moderate essential hypertension**
- **Adult** (By Mouth): 200 micrograms once daily for 3 weeks, dose to be taken in the morning, then increased if necessary to 400 micrograms daily in 1-2 divided doses (max. per dose 400 micrograms), maximum daily dose to be given in 2 divided doses; maximum 600 micrograms per day.
Cautions
First-degree AV block; moderate heart failure; severe coronary artery disease; unstable angina Cautions, further information Elderly For centrally-acting antihypertensives, Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) criteria to aid medication reviews (see Prescribing in the elderly for information): potentially inappropriate unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives (generally less well tolerated by older people).
Contraindications
Bradycardia; second- or third-degree AV block; severe heart failure; sick sinus syndrome; sino-atrial block
Side effects
Common or very common Asthenia; diarrhoea; dizziness; drowsiness; dry mouth; dyspepsia; headache; insomnia; nausea; pain; skin reactions; vertigo; vomiting Uncommon Angioedema; bradycardia; nervousness; oedema; syncope; tinnitus
Interactions
**Other interactions (6):**
- Concomitant administration of moxonidine and other antihypertensive medicinal products result in an additive effect.
- Since tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive medicinal products, it is not recommended that tricyclic antidepressants be co-administered with...
- Moxonidine can potentiate the sedative effect of tricyclic anti-depressants (avoid co-prescribing), tranquillisers, alcohol, sedatives and hypnotics.
- Moxonidine moderately augmented the impaired performance in cognitive functions in subjects receiving lorazepam.
- Moxonidine may enhance the sedative effect of benzodiazepines when administered concomitantly.
- Moxonidine is excreted through tubular excretion.
Pregnancy
Manufacturer advises avoid-no information available.
Breast feeding
Present in milk-manufacturer advises avoid.
Renal impairment
Avoid if eGFR less than 30 mL/minute/1.73 m 2 . Dose adjustments Max. single dose 200 micrograms and max. daily dose 400 micrograms if eGFR 30-60 mL/minute/1.73 m 2 .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Moxonidine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

